N-(2-Chlor-aethyl)-p-chlor-benzolsulfonamid | 4875-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-Chlor-aethyl)-p-chlor-benzolsulfonamid
• 英文别名: N-2-chloroethyl-p-chlorobenzenesulfonamide；4-chloro-N-(2-chloroethyl)benzenesulfonamide
• CAS: 4875-54-1
• 化学式: C₈H₉Cl₂NO₂S
• 分子量: 254.137
• InChiKey: XPEVMFJXCOKEJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-Chlor-aethyl)-p-chlor-benzolsulfonamid 在 哌啶 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (Z)-4-chloro-N-(2-(4-((2,4-dioxothiazolidine-5-ylidene)methyl)phenoxy)ethyl)benzenesulfonamide
  参考文献：
  名称：

  带有苯磺酰胺部分的新型5-亚苄基噻唑烷-2,4-二酮的合成与生物评价

  摘要：

  设计并合成了两个系列的带有苯磺酰胺部分的新的5-亚苄基噻唑烷-2,4-二酮。评价了合成的化合物的几种生物学活性，包括细胞毒性，组蛋白脱乙酰化和蛋白磷酸酶1B（PTP1B）抑制作用。发现在苯磺酰胺部分上具有氯取代基的那些5-亚苄基噻唑烷-2，4-二酮显示出明显的细胞毒性，与用作阳性对照的SAHA相当。几种细胞毒性化合物还表现出对组蛋白脱乙酰基的抑制作用，表明这些化合物可能具有组蛋白脱乙酰基酶的抑制特性。但是，这些化合物对PTP1B的活性没有明显的抑制作用。

  DOI：

  10.1007/s00044-015-1422-9
• 作为产物：
  描述：

  4-氯-N-(2-羟基乙基)苯磺酰胺 在 吡啶 、 氯化亚砜 作用下， 生成 N-(2-Chlor-aethyl)-p-chlor-benzolsulfonamid
  参考文献：
  名称：

  Jensen; Buchardt, Acta Chemica Scandinavica (1947), 1961, vol. 15, p. 447

  摘要：

  DOI：

文献信息

• Glutamic acid receptor agonist
  申请人：Nippon Suisan Kaisha, Ltd.

  公开号：US05955505A1

  公开（公告）日：1999-09-21

  A method comprising administering a sulfonamide derivative to a patient requiring activation of glutamate receptors, the sulfonamide derivative represented by the formula ##STR1## wherein A is a napthyl group, a pyridyl group, a phenyl group, a phenyl group substituted by 1 to 5 members selected from the group consisting of a halogen atom, an alkyl group having 1 to 40 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a nitro group, and an acetamido group, or an alkyl group having 1 to 20 carbon atoms; B is an alkylene group having 1 to 3 carbon atoms, a group of --OCH.sub.2 -- or a group of --CH.dbd.CH--; X and Y are the same or different, and are each a hydrogen atom or a fluorine atom; R is a carboxy group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a hydroxymethyl group or a group of ##STR2## wherein R.sub.1 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and R.sub.2 is a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, a carboxymethyl group or an alkoxycarbonylmethyl group having 3 to 6 carbon atoms; m is an integer from 0 to 2; and n is an integer from 0 to 3, or an pharmaceutically acceptable salt thereof, as an effective ingredient. The agonist is efficacious in the medical treatment of nerve degenerative disorders.

  一种方法包括向需要激活谷氨酸受体的患者施用磺胺衍生物，所述磺胺衍生物由以下式表示：其中A为萘基、吡啶基、苯基、被1至5个成员选自卤原子、具有1至40个碳原子的烷基、具有1至4个碳原子的烷氧基、硝基和乙酰氨基的苯基取代的苯基，或者具有1至20个碳原子的烷基；B为具有1至3个碳原子的烷基、--OCH.sub.2--基团或--CH.dbd.CH--基团；X和Y相同或不同，分别为氢原子或氟原子；R为羧基、具有2至5个碳原子的烷氧羰基、羟甲基基团或##STR2##基团，其中R.sub.1为氢原子或具有1至3个碳原子的烷基；R.sub.2为氢原子、羟基、具有1至3个碳原子的烷基、羧甲基基团或具有3至6个碳原子的烷氧羰基甲基基团；m为0至2的整数；n为0至3的整数，或其药学上可接受的盐，作为有效成分。该激动剂在神经退行性疾病的医疗治疗中具有疗效。
• Fused pyrimidinone matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030004172A1

  公开（公告）日：2003-01-02

  Selective MMP-13 inhibitors are fused pyrimidinones of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical 2 X is O, S, SO, SO 2 , NR 5 , or CH 2 ; 3 B is O or NR 5 ; or A and B are taken together to form —C≡C—; R 1 , R 4 , and R 5 are hydrogen, alkyl, alkenyl, alkynyl, (CH 2 ) n aryl, (CH 2 ) n cycloalkyl, C 1 -C 6 alkanoyl, or (CH 2 ) n heteroaryl; R 2 and R 3 are hydrogen, alkyl, alkenyl, alkynyl CN, NO 2 , NR 4 R 5 , (CH 2 ) n cycloalkyl, (CH 2 ) n aryl, or (CH 2 ) n heteroaryl; R 2 may further be halo; n is an integer of from 0 to 5; and R 4 and R 5 when taken together with a nitrogen to which they are both attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R 1 and R 3 are not both selected from hydrogen and C 1 -C 6 alkyl.

  选择性MMP-13抑制剂是具有以下结构的嘧啶酮类化合物或其药用盐： 其中： W与其连接的碳原子一起形成一个5元环二自由基； X为O、S、SO、SO2、NR5或CH2； B为O或NR5； 或A和B结合形成—C≡C—； R1、R4和R5为氢、烷基、烯基、炔基、( )n芳基、( )n环烷基、C1-C6烷酰基或( )n杂环芳基； R2和R3为氢、烷基、烯基、炔基、CN、NO2、NR4R5、( )n环烷基、( )n芳基或( )n杂环芳基；R2还可以是卤素； n为0到5的整数； R4和R5与它们都连接的氮一起形成含碳原子且可选择含有O、S或N的3-8元环，可以是取代或未取代的； 但要注意R1和R3不同时选择自氢和C1-C6烷基。
• 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors
  申请人：Dannhardt Gerd

  公开号：US20070185169A1

  公开（公告）日：2007-08-09

  The invention relates to the 2-mercapto-4,5-diarylimidazole derivatives of formula (I), wherein R 1 , R 2 , R 3 and R 4 are defined as in the description. The inventive compounds have an immunomodulatory and cyclooxygenase-inhibiting activity and are therefore suitable for the treatment of disease that are associated with a disturbed immune system.

  本发明涉及公式（I）中的2-巯基-4,5-二芳基咪唑衍生物，其中R1、R2、R3和R4如说明书中所定义。这些创新化合物具有免疫调节和环氧合酶抑制活性，因此适用于治疗与免疫系统紊乱相关的疾病。
• Sulfonamide derivatives
  申请人：TAISHO PHARMACEUTICAL CO. LTD

  公开号：EP0469901A1

  公开（公告）日：1992-02-05

  Sulfonamide derivative, useful as blood platelet aggregation inhibitors, have the formula: in which A is a naphthyl group, a pyridyl group, a phenyl group, a phenyl group substituted by 1 to 5 substituents selected from halogen atoms, alkyl groups having 1 to 4 carbon atoms, alkoxy groups having 1 to 4 carbon atoms, nitro groups and acetamido groups, or an alkyl group having 1 to 20 carbon atoms; B is an alkylene group having 1 to 3 carbon atoms, a group -OCH₂- or a group -CH=CH-; X and Y are the same or different, and each is a hydrogen or fluorine atom; R is a carboxy group, an alkyoxycarbonyl group having 2 to 5 carbon atoms, a hydroxymethyl group or a group of the formula (in which R¹ is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; R² is a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, a carboxymethyl group or an alkoycarbonylmethyl group having 3 to 6 carbon atoms); m is 0, 1 or 2; n is 0,1,2 or 3; or salts thereof. This invention also provided intermediates for the preparation of the sulfonamide, which intermediates are thiophenols of the formula: (in which R, X and Y are as defined above).

  磺酰胺衍生物可用作血小板聚集抑制剂，其化学式为 其中 A 是萘基、吡啶基、苯基、被 1 至 5 个取代基取代的苯基，取代基可选 自卤素原子、1 至 4 个碳原子的烷基、1 至 4 个碳原子的烷氧基、硝基和乙酰氨基， 或 1 至 20 个碳原子的烷基；B 是具有 1 至 3 个碳原子的亚烷基、基团-OCH₂- 或基团-CH=CH-； X 和 Y 相同或不同，各自是氢原子或氟原子； R 是羧基、具有 2 至 5 个碳原子的烷氧羰基、羟甲基或式如下的基团 (其中，R¹是氢原子或具有 1 至 3 个碳原子的烷基；R²是氢原子、羟基、具有 1 至 3 个碳原子的烷基、羧甲基或具有 3 至 6 个碳原子的烷酰基甲基）；m 是 0、1 或 2；n 是 0、1、2 或 3；或其盐。 本发明还提供了制备磺酰胺的中间体，这些中间体是式中的噻吩酚： (其中 R、X 和 Y 如上定义）。
• GLUTAMIC ACID RECEPTOR AGONIST
  申请人：NIPPON SUISAN KAISHA, LTD.

  公开号：EP0811375A1

  公开（公告）日：1997-12-10

  A glutamic acid receptor agonist which comprises as the active ingredient sulfonamide derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof wherein A represents naphthyl, pyridyl, phenyl optionally having 1 to 5 substituents selected from the group consisting of halogeno, C1-4 alkyl, C1-4 alkoxy, nitro and acetamido, or C¿1-20 alkyl; B represents C¿1-3 alkylene, -OCH2- or -CH=CH-; X and Y are the same or different and each represents hydrogen or fluoro; R represents carboxy, C2-5 alkoxycarbonyl, hydroxymethyl or (a) (wherein R1 represents hydrogen or C1-3 alkyl; and R2¿ represents hydrogen, hydroxy, C1-3 alkyl, carboxymethyl or C¿3-6 alkoxycarbonyl); m represents an integer of 0 to 2 and n represents an integer of 0 to 3. The agonist is efficatious in the prevention and treatment of nerve degeneration in morbid conditions.

  一种谷氨酸受体激动剂，其活性成分包括通式(I)所代表的磺酰胺衍生物或其药学上可接受的盐 其中A代表萘基、吡啶基、苯基，可任选具有1至5个取代基，这些取代基选自由卤素、C1-4烷基、C1-4烷氧基、硝基和乙酰氨基或C¿1-20烷基组成的组；B代表C¿1-3亚烷基、-OCH2-或-CH＝CH-；X和Y相同或不同，各自代表氢或氟；R代表羧基、C2-5烷氧基羰基、羟甲基或(a)（其中R1代表氢或C1-3烷基；R2¿代表氢、羟基、C1-3烷基、羧甲基或C¿3-6烷氧基羰基）；m代表0至2的整数，n代表0至3的整数。该激动剂对预防和治疗病态情况下的神经变性具有疗效。